Secondly, some RCTs lacked detailed reporting on the arrhythmia history of participants, such as paroxysmal AF/AFL and persistent AF/AFL, which might complicate the accurate evaluation of SGLT2 inhibitors’ effects. This evidence concerns the gene SLC5A2 and Paroxysmal atrial fibrillation.